Peptide marketing is the question every clinic, compounder and distributor is asking this quarter. The answer rests on one FDA page that changes and on claim rules that do not. This post gives you seven rules for what you may say about peptides, where to check a substance’s status, and how to keep a page honest each month.
TLDR: Peptide marketing starts with one question: is this substance an approved drug, a compounded drug, or neither. The FDA’s 503A bulk drug substances page is the reference, and it changes, so every status statement gets a date. No disease or outcome claims for any compounded or unapproved peptide, no matter what the label says. Many peptides clinics ask about sit in no category and get no availability line at all. Where counsel confirms a substance may be compounded, the line stays factual and education-first. Read on for the seven rules, the mistakes we see most, and a short monthly check.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.
Everyone is asking about peptides this quarter. Clinics, compounders and distributors alike. It is the newest fad, pushed by GLP-1 demand and by influencers on TikTok selling what I call hopeium. The calls all sound the same. What can we say, and where do we check?
The answer has two parts. The claim rules are old and stable. The product status is not, and it lives on an FDA page with a date at the bottom. This post covers both: seven rules for peptide marketing, the mistakes we see, and a monthly routine that keeps a page current.
Why Peptide Marketing Is Harder Than It Looks
Peptide marketing is hard because one word covers three different legal things. A peptide can be the active ingredient in an approved drug. It can be a bulk substance a compounder uses under Section 503A of the Food, Drug, and Cosmetic Act. Or it can be neither, sold in a vial with a label that says it is for research.
Each bucket allows a different set of words. A page that mixes them borrows the strongest claim from the first bucket and hangs it on the third. That is where the trouble starts.
The second problem is evidence. When we ask a practice or a vendor what stands behind a peptide sentence, the answer is usually vendor materials. Sometimes a certificate of analysis or a public trial. Often not much at all. The influencer who made the claim famous has no file. The clinic that copied it has none either.
So the work has two halves. Sort the substance into the right bucket, then say only what that bucket allows. The sorting starts on one FDA page.
The FDA 503A Page Is the Reference, and It Changes
The FDA’s 503A bulk drug substances page is where a compounded peptide’s status lives. When I checked it for this article, the 503A page showed a content date of May 14, 2026. Every status line below reflects that date and only that date. If you are reading this later, open the page before you trust a word of it.
Section 503A covers drugs compounded by a licensed pharmacist or physician for an individual patient. A bulk drug substance may be used in 503A compounding if it meets one of three conditions, among others. It complies with an applicable USP or NF monograph. It is a component of an FDA-approved drug. Or it appears on the FDA’s 503A bulks list. Counsel confirms the rest. Many nominated substances meet none of the three yet.
For those, the FDA 503A bulk drug substances page describes an interim policy with three categories. Two terms first. A nominated substance is one someone asked the FDA to add to the list. Enforcement discretion means the FDA has said it does not intend to act while set conditions are met.
| Category | What the FDA page says | What it means for a page |
|---|---|---|
| Category 1 | Nominated with enough data to review, may be eligible for the list, and not on any other list | The FDA does not intend to act against a compounder using it, if the guidance conditions are met |
| Category 2 | Nominated with enough data, but the FDA has found significant safety risks pending further review | The FDA says it would consider action under its general enforcement policies |
| Category 3 | Nominated with too little data for the FDA to review | Not covered by the Category 1 policy |
Those three rows decide most of what a page may imply about supply.
Two more things on the page matter. First, the FDA page notes guidance saying the agency does not intend to place substances nominated on or after January 7, 2025 into these categories. A newly nominated peptide may sit in no bucket at all. Second, the page itself names no substances. The names sit in a linked list the FDA updates.
I am not repeating any peptide’s category here. The list can change between the day I write and the day you read. Open the page, open the list, and write down the date shown. That habit is Rule 2, and the rest follow it.
One dated fact is worth stating, because clinics keep getting it wrong. In April 2026, the FDA took twelve well-known peptides off Category 2 after their nominations were withdrawn. An FDA advisory committee discussed seven of them on July 23 and 24, 2026. As of October 2, 2026, I have found no FDA action that puts any of them in Category 1 or on the 503A bulks list. Off Category 2 is not the same as cleared to compound.
The Seven Rules of Peptide Marketing
The seven rules take a page from what everyone says to what this practice can defend. Run them on every page, caption, deck and rep script that mentions a peptide.
Rule 1: Sort the Substance Before You Write
Before a word is written, sort the substance. Approved drug, compounded drug, or neither. A compounded drug’s bulk substance meets one of the three 503A conditions above, or sits in Category 1 under the FDA page’s interim policy. The answer sets the ceiling on every line that follows. If nobody in the practice can answer in one sentence, the page is not ready.
For an approved drug, the approved labeling sets the limits. For a compounded product, those 503A conditions, the FDA page, and state pharmacy law set them. For the third bucket there is no ceiling to find, because there is no lawful clinical product to market. Counsel decides which bucket fits the practice’s own supply.
Rule 2: Date Every Status Statement
Every sentence about status carries the date you read it. “As of the FDA page dated May 14, 2026” is the form. A status sentence without a date is a claim about today, and today keeps moving.
This sounds fussy until the list changes. A practice that dated its page can show what it knew and when. A practice that did not is defending a line that may have been true once.
Rule 3: No Disease or Outcome Claims for Compounded or Unapproved Peptides
No compounded or unapproved peptide gets a disease claim or an outcome claim on any page. The FTC’s Health Products Compliance Guidance asks for competent and reliable scientific evidence behind health claims. For health benefit claims, it says randomized, controlled human clinical trials are generally what experts would require. Vendor sheets and influencer clips are not that.
The FDA side is simpler. A product marketed to treat a disease is being marketed as a drug. The FDA’s consumer alert on regenerative medicine products covers stem cells and exosomes, not peptides. But its logic is the one a reviewer applies to any unapproved product. So “supports recovery,” “heals tissue” and “reverses aging” are all do-not-use lines for a compounded peptide.
Rule 4: A Research Label Does Not License a Clinic
A vial labeled “for research use only” or “not for human use” is not a clinical product. A clinic may not market it as one. The label states the seller’s intent. It does not change what happens when a practice puts the product on a page next to a booking button.
Intended use follows the marketing, not the sticker. Counsel decides the practice’s own exposure, but the peptide marketing rule is plain. If it is labeled for research, it does not belong on a patient-facing page at all.
Rule 5: No Availability Claims for Substances the FDA Has Flagged
If the FDA page places a substance in Category 2, a page that promotes it is promoting a product the FDA has flagged. The FDA has said it would consider action for compounding with those substances. “Now offering” and “ask about our” are availability claims, and they read as such.
The same caution applies to any substance that sits in no category. That covers one nominated on or after January 7, 2025. It also covers one taken off Category 2 because its nomination was withdrawn. Unless it meets one of the three bulk conditions, no category is not clearance. It is silence, and silence is not a marketing asset. Counsel confirms.
Rule 6: Educate, Do Not Sell
Education about peptides is allowed. Sales language is not, for anything in the compounded or research-labeled buckets. The difference is not the topic. It is the net impression, which the FTC guidance judges from the ad as a whole.
A page that explains what a peptide is, how the FDA sorts bulk substances, and what a consult covers is education. A page that names a peptide, lists benefits, and ends with a booking link is a sale. It stays a sale no matter how many times it says “educational.” Our traffic light guide to what clinics can and cannot say sorts these lines fast.
Rule 7: Review the Page Monthly
Put the FDA 503A page on a monthly calendar. Open it, check the content date, open the list, and compare it to every status line you have live. If a category moved, update the page the same day and record the change.
That review takes minutes when the page is dated. It is the one rule that keeps the other six true, because status is the only part of peptide marketing that moves.
Those are the rules. Here are the ways practices break them without meaning to.
Common Peptide Marketing Mistakes We See
The most common peptide marketing mistake is drift. Almost none of the exposure we find in clinic marketing was put there on purpose. It drifts one word at a time, from “being studied for” to “helps” to “treats,” usually in a subheading nobody thinks of as copy. Peptide pages drift faster than most, because the influencer version starts at “treats.”
The second mistake is copying the influencer. A TikTok claim has no file behind it. A practice that repeats it owns the claim with none of the cover. The FDA warning letters we read describe unapproved products by claim type, and the claims usually started somewhere else. We break down how FDA warning letters work in a separate guide.
Third, borrowing the approved drug’s language. A compounded product is not the approved drug, even when the active ingredient shares a name. Approved labeling belongs to the approved product. A compounded page that lifts it is making a claim it cannot hold.
Fourth, trusting the vendor deck. When a product company hands us a deck to review, we flag three things first. Claims that are not compliant, wording too complex for the buyer, and weak graphics. A rep’s slide does not become evidence when a clinic pastes it.
Fifth, hiding the sale inside “education.” A page can be one word away from a letter even when the header says educational. Reviewers read the whole page, buttons included.
Here is what all seven rules look like on one page.
One Practice, One Peptide Page, and the Monthly Check
Picture a wellness practice in a mid-sized city that added peptides last spring. The page names three peptides, calls them “next-generation recovery therapy,” lists benefits under each, and ends with a booking button. Two of the three came in vials that read “for research use only.” Do not use that page. Here is the rebuild.
Rule 1. The practice sorts the three. One is compounded from a bulk substance with a category on the FDA page. Two are research-labeled products, and they come off the page under Rule 4. Counsel confirms the practice’s position on the compounded one.
Rule 2. The remaining status line gets a date: the FDA page’s content date, read that morning.
Rule 3. Every benefit line comes off. “Recovery therapy” comes off. The page now says what a peptide is and what the FDA page says about this substance, with the date. No outcome. No condition.
Rules 5 and 6. Because the substance sits in Category 1 as of that date, counsel may allow one plain availability line, with the date. That would not be true for a peptide that sits in no category, including the ones taken off Category 2 in April 2026. Those get a status explainer and nothing more. Compounded drugs are not FDA approved, so that line carries no outcome claim. It stays factual and education-first. The booking link sits after the education, not inside it. Counsel signs off on that line.
Rule 7. The practice manager adds a monthly reminder. First Monday: open the FDA page, check the date, compare the list, record either way.
Counsel decides whether the rebuilt page is right for that practice in that state. The seven rules got it to the point where counsel had something clean to decide. Getting a page to that point is the job our regen marketing compliance support is built for.
Frequently Asked Questions
What Is Peptide Marketing Allowed to Say in 2026?
Peptide marketing may educate. It may describe a product and invite a consult only for an FDA-approved peptide drug, or for a substance counsel confirms may lawfully be compounded. For a peptide that sits in no category, a dated status explainer is the ceiling. It may not attach a disease or outcome claim to any compounded or unapproved peptide. Status lines about a compounded substance should cite the FDA’s 503A bulk drug substances page and carry the date it was read. Counsel confirms the fit for each practice and state.
Where Do I Check a Peptide’s Compounding Status?
The FDA’s 503A bulk drug substances page, and the list it links to. The page describes three categories for nominated substances and shows a content date at the bottom. When I checked for this article, the page date was May 14, 2026. Record the date before you write a status line.
Does a “Research Use Only” Label Protect the Clinic?
No. The label states the seller’s intent. It does not make a product lawful to market for patient use, and a page that promotes a research-labeled product to patients says the opposite. Keep research-labeled products off patient-facing pages. Counsel decides the exposure on any product already in use.
Can a Clinic Use the Approved Drug’s Claims for a Compounded Version?
No. Approved labeling belongs to the approved product. A compounded product is a different product, even when the active ingredient shares a name. Any claim on a compounded peptide page must stand on its own evidence, which is the FTC standard.
Is Peptide Marketing Different From Stem Cell Marketing?
The claim rules are the same. The status source is different. Stem cell and exosome status runs through the FDA’s tissue rules and its consumer alert, which we covered in what you can say about stem cells. Peptide status runs through drug compounding rules and the 503A page. Same discipline, different bookmark.
Key Takeaways
- In peptide marketing, a substance is an approved drug, a compounded product from a bulk substance, or neither, and each bucket allows different words.
- The FDA’s 503A page is the status reference; it showed a content date of May 14, 2026 when this was written, and it changes.
- No disease or outcome claim attaches to any compounded or unapproved peptide, and approved drug claims do not carry over.
- A research-use label does not license a clinic to market a product, and flagged substances get no availability claims.
- Education is allowed, sales language is not, and the whole page’s net impression is what gets judged.
- Review the FDA page monthly, date every status line, and record each check.
Your Next Step
Most peptide pages we see were written from a supplier deck and an influencer clip, with no date and no file. Regen Portal builds the claims inventory first, sorts each substance into its bucket, and rewrites the page down to what the practice can defend. The claims substantiation routine we published this month runs underneath all of it.
PS: Send us one peptide service page or one product one-pager and we will run a free compliance audit on it.
Email: hello@regenportal.com
YouTube: Subscribe to the channel
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
